Precision Diabetes Management: Integrated East-West Approach

December 14, 2025 updated by: Xinhua Xiao, Peking Union Medical College Hospital

Construction of a Precision and Individualized Management Model for Diabetes With Integrated Traditional Chinese and Western Medicine

This project will leverage a large-scale cohort of early-onset type 2 diabetes patients to conduct innovative prospective clinical research. By integrating traditional Chinese medicine diagnostic information, clinical data, laboratory results, continuous glucose monitoring, genetic information, multi-omics data, and multi-modal monitoring data, and utilizing advanced data analysis methods such as deep learning, the project aims to establish a comprehensive monitoring, precise classification, and personalized diagnosis and treatment model-a holistic management approach integrating traditional Chinese and Western medicine for early-onset type 2 diabetes. This initiative is expected to enhance the management of early-onset type 2 diabetes, improve treatment outcomes and quality of life for affected patients, pioneer an innovative path for personalized integrated traditional Chinese and Western medicine management in this population, and promote the application of precision medicine in diabetes prevention and treatment.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

2000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

The age at type 2 diabetes diagnosis is ≥18 years but <40 years.

Description

Inclusion Criteria:

  • The age at diabetes diagnosis is ≥18 years but <40 years.

Exclusion Criteria:

  • The clinical diagnosis was type 1 diabetes, and at the time of enrollment, antibody levels or insulin/C-peptide results still supported the original diagnosis.

There were clear secondary factors contributing to hyperglycemia, such as Cushing's syndrome or pheochromocytoma.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Integrated Traditional Chinese and Western Medicine Management
Other: No interventions
No interventions

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Traditional Chinese Medicine Syndrome Score
Time Frame: Through study completion, an average of 3 months
Through study completion, an average of 3 months
HbA1c
Time Frame: Through study completion, an average of 3 months
Through study completion, an average of 3 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Triglycerides
Time Frame: Through study completion, an average of 3 months
Through study completion, an average of 3 months
High-Density Lipoprotein Cholesterol
Time Frame: Through study completion, an average of 3 months
Through study completion, an average of 3 months
Total Cholesterol
Time Frame: Through study completion, an average of 3 months
Through study completion, an average of 3 months
Fasting Blood Glucose
Time Frame: Through study completion, an average of 3 months
Through study completion, an average of 3 months
Low-Density Lipoprotein Cholesterol
Time Frame: Through study completion, an average of 3 months
Through study completion, an average of 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Peking Union Medical College Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 31, 2025

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

March 31, 2027

Study Registration Dates

First Submitted

December 1, 2025

First Submitted That Met QC Criteria

December 14, 2025

First Posted (Actual)

December 29, 2025

Study Record Updates

Last Update Posted (Actual)

December 29, 2025

Last Update Submitted That Met QC Criteria

December 14, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • CXZH2024059

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Early-Onset Type 2 Diabetes

Clinical Trials on No interventions

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe